EN | RU
EN | RU

Help Support

Back

Use of Abrocitinib for atopic dermatitis in adults and adolescents

Atopic dermatitis Atopic dermatitis
Atopic dermatitis Atopic dermatitis

This post-hoc analysis sought to assess the prolonged effectiveness of continuous and decreased-dose Abrocitinib, withdrawal, and therapy reintroduction reaction after flare in JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN participants.

See All

Key take away

Abrocitinib [Janus kinase (JAK) inhibitor], whether through varied dosing strategies, proves effective and safe in enhancing the quality of life for both adults and adolescents with moderate-to-severe atopic dermatitis.

Background

This post-hoc analysis sought to assess the prolonged effectiveness of continuous and decreased-dose Abrocitinib, withdrawal, and therapy reintroduction reaction after flare in JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN participants.

Method

Individuals (aged 12 to 17 years) and adults suffe atopic dermatitis (AD) responding to Abrocitinib 200 mg induction were picked. They were allocated to 40 weeks’ maintenance using placebo or Abrocitinib (200 mg/100 mg). Those encountering a flare-up or itch during maintenance obtained the rescue therapy.

Result

Out of 246 adolescents, 145 (58.9%), and among 981 adults, 655 (66.8%) responded to the induction. They experienced comparable proportions of flare during maintenance with Abrocitinib and placebo, as shown in the following Table 1:

The percentage of participants experiencing the Eczema Area and Severity Index (EASI) response and the Investigator's Global Assessment (IGA) response is illustrated in the following Table 2:

Abrocitinib showed consistent safety across ages, with higher nausea incidence in adolescents.

Conclusion

Abrocitinib therapy is useful for avoiding flare-ups in AD-affected adolescents and adults.

Source:

Journal of Dermatological Treatment

Article:

Efficacy and safety of Abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

Authors:

Carsten Flohr et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: